Novartis India has launched Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto is the country's first regulatory authority-approved radioligand therapy for eligible patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India.
Novartis India is a pharmaceutical company. The business operations of the Company include Pharmaceuticals, Generic, over the counter (OTC) and Animal Health.
